Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism

Mühlen, A. Zur; Schwarz, C.; Mehnert, W.

doi:10.1016/s0939-6411(97)00150-1

Cited by 793 publications

(370 citation statements)

References 7 publications

Supporting

Mentioning

330

Contrasting

Unclassified

Order By: Relevance

“…Conversely, the initial release burst for nanoparticles prepared using Compritol ® was less than 40 % within the first 20 minutes. The reason for the high initial release of edelfosine from the stearic acid nanoparticles could be the diffusion release of edelfosine distributed near the surface and in the outer portion of the nanoparticles [12]. These results were in accordance with the observations made by DSC and X-ray diffractometry.…”

Section: In Vitro Release Studiessupporting

confidence: 89%

See 1 more Smart Citation

Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization

Mendoza

Rayo

Mollinedo

et al. 2008

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

The ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, edelfosine ) is the prototype molecule of a promising class of antitumour drugs named alkyl-lysophospholipid analogues (ALPs) or antitumor ether lipids. This drug presents a very important drawback as can be the dose depending haemolysis when administered intravenously. Lipid nanoparticles have been lately proposed for different drug encapsulation as an alternative to other controlled release delivery systems, such as liposomes or polymeric nanoparticles. The aim of this study was to develop a lipid nanoparticulate system that would decrease systemic toxicity as well as improve the therapeutic potential of the drug. Lipids employed were Compritol ® 888 ATO and stearic acid. The nanoparticles were characterized by photon correlation spectroscopy for size and size distribution, and atomic force microscopy (AFM) was used for the determination of morphological properties. By both differential scanning calorimetry (DSC) and X-ray diffractometry, crystalline behaviour of lipids and drug was assessed.The drug encapsulation efficiency and the drug release kinetics under in vitro conditions were measured by HPLC-MS. It was concluded that Compritol ® presents advantages as a matrix material for the manufacture of the nanoparticles and for the controlled release of edelfosine.

show abstract

Section: In Vitro Release Studiessupporting

confidence: 89%

“…These particulate systems made from solid lipids started being developed in the early nineties. They provide physical stability, controlled release and a wide variety of application routes (parenteral, oral, dermal, ocular, pulmonary and rectal) [12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization

Mendoza

Rayo

Mollinedo

et al. 2008

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

show abstract

“…SLN cooling curve shows a main peak at 55.68°C which can be attributed to the beta modification. But if the SLN cooling curve of the peak higher than 62°C suggested the presence of alpha modifications (Zur Muhlen et al, 1998). Solid lipid nanoparticles do not, as proposed, "combine the advantages of other colloidal drug carriers and avoid the disadvantages of them".…”

Section: Discussionmentioning

confidence: 99%

Characterization of Nigella Sativa L. Essential Oil-Loaded Solid Lipid Nanoparticles

Al-Haj¹,

Shamsudin²,

Alipiah³

et al. 2010

American Journal of Pharmacology and Toxicology

View full text Add to dashboard Cite

Problem statement: Seeds of Nigella sativa L., commonly known as black seed, have been used in traditional medicine by many Asian, Middle Eastern and Far Eastern Countries to treat headache, coughs, abdominal pain, diarrhea, asthma, rheumatism and other diseases. The seeds of this plant are the most extensively studied, both phytochemically and pharmacologically. The aqueous and oil extracts of the seeds have been shown to possess especially nowadays in pharmaceutical antioxidant, anti-inflammatory, anticancer, analgesic, antimicrobial activities and medicinal and cosmetic applications, sanitary, cosmetic, agricultural and food industries. Approach: The aim of this study was to formulate a new delivery system for dermal and cosmetic application by the incorporation of Nigella sativa essential oil into solid lipid nanoparticles SLN. SLN formulations were prepared following the high-pressure homogenization after starring and ultra-trax homognization techniques using hydrogenated palm oil Softisan 154 and N. sativa essential oil as lipid matrix, sorbitol and water as surfactants. The SLN formulation particle size was determined using Photon Correlation System (PCS). Results: The change of particle charge was studied by Zeta Potential (ZP) measurements, while the melting and re-crystallization behavior was studied using Differential Scanning Calorimetry (DSC). Data showed a high physical stability for both formulations at various storage temperatures during 3 months of storage. In particular, average diameter of N. sativa essential oilloaded SLN did not vary during storage and increased slightly after freeze-drying the SLN dispersions. Conclusion: Therefore, obtained results showed that the studied SLN formulations are suitable carriers in pharmaceutical and cosmetic fields.

show abstract

“…The size effect may also partly explain the low release from the larger size SLN. The prerequisite for fast drug release are the small molecular size, large surface area, and a high drug ofile olease prdiffusion coefficient (Zur Muhlen et al, 1998;Zhang et al, 2008). The reduced drug diffusion mobility in SLN with large particle could explain the decreased drug release rate.…”

Section: In Vitro Releasementioning

confidence: 99%

Development of nanostructured lipid carriers for controlled delivery of mefenamic acid

Khurana

Bedi

Jain

2012

IJBNN

View full text Add to dashboard Cite

This study was aimed to develop nanostructured lipid carriers (NLC) for the possible delivery of mefenamic acid. This study describes the effect of liquid lipid concentration on the characteristics of NLC such as particle size, polydispersity index, zeta potential, drug entrapment efficiency, and occlusivity index. Transmission electron microscopy revealed nearly spherical shape NLC with negligible effect of liquid lipid content on the particle morphology. The differential scanning calorimetry demonstrated a depression in the melting point and crystallinity index of the NLC with an increase in the amount of liquid lipid. The in vitro drug release studies demonstrated that solid lipid nanoparticle (0% oil), and NLC possessed a biphasic release pattern characterised by a rapid initial release followed by a sustained release, in comparison to nanoemulsions (100% oil) of which a nearly constant release was observed. Compared to NE and SLN, the excellent physical stability of NLC against drug leakage was seen.

show abstract

Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism

Cited by 793 publications

References 7 publications

Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization

Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization

Characterization of Nigella Sativa L. Essential Oil-Loaded Solid Lipid Nanoparticles

Development of nanostructured lipid carriers for controlled delivery of mefenamic acid

Contact Info

Product

Resources

About